On Wednesday, Mankind Pharma said that it has agreed with Dr Reddy’s Laboratories (DRL) to acquire two of its brands – one asthma and one infant care brand. The deal size was not disclosed.
- Govt plans new route connecting Noida airport to NH-34
- India Ranks Third in Global Fintech Funding, Despite 33% Drop in 2024
- India’s Retail Inflation Drops to 5.22% in December, Food Inflation at 8.39%
- Donald Trump Inauguration: Xi Jinping Invited, S Jaishankar to Represent India
- What Is Currency Appreciation: Working & Cause Of Currency Appreciation
Combihale, a drug used for treating asthma and chronic obstructive pulmonary disease, has a category market size of Rs 900 crore, growing at 14 per cent (IQVIA). Daffy, a soap-free moisturizing bar for infants, operates in a market category valued at Rs 1000 crore and is growing at 18 per cent (IQVIA).
The company said that the acquisition of Combihale is expected to strengthen Mankind’s presence in the inhalation respiratory market segment.
